The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity | MicrobiomeTrials← Back to trialsNCT06494878
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06-04Est. Completion: 2030-09
Enrollment target: 8,805 participants Locations- Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann, Brussels, Belgium
- Foothills Medical Centre, Calgary, Alberta, Canada
- The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
- Hvidovre Hospital, Hvidovre, Capital Region, Denmark
- CHU de Nancy, Nancy, France
- APHP - Hôpital Port Royal, Paris, France
- CHU de Saint-Etienne, Saint-Etienne, France
- CHU de Toulouse, Toulouse, France
- Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology, Dublin, Ireland
- UCD Centre for Human Reproduction, The Coombe Hospital, Dublin, Ireland
- Amsterdam UMC, Amsterdam, Netherlands
- Medical University of Warsaw, Warsaw, Poland
Other microbiome trials you might be interested in
Arterial ThromboembolismVenous ThromboembolismPulmonary Embolism
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodi…
Huntsville, United StatesEst. completion Mar 2030
Persistent Atrial Fibrillation
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation…
Birmingham, United StatesEst. completion Feb 4, 2026